TY - JOUR
T1 - Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients
AU - Jarius, Sven
AU - Ruprecht, Klemens
AU - Wildemann, Brigitte
AU - Kuempfel, Tania
AU - Ringelstein, Marius
AU - Geis, Christian
AU - Kleiter, Ingo
AU - Kleinschnitz, Christoph
AU - Berthele, Achim
AU - Brettschneider, Johannes
AU - Hellwig, Kerstin
AU - Hemmer, Bernhard
AU - Linker, Ralf A.
AU - Lauda, Florian
AU - Mayer, Christoph A.
AU - Tumani, Hayrettin
AU - Melms, Arthur
AU - Trebst, Corinna
AU - Stangel, Martin
AU - Marziniak, Martin
AU - Hoffmann, Frank
AU - Schippling, Sven
AU - Faiss, Juergen H.
AU - Neuhaus, Oliver
AU - Ettrich, Barbara
AU - Zentner, Christian
AU - Guthke, Kersten
AU - Hofstadt-van Oy, Ulrich
AU - Reuss, Reinhard
AU - Pellkofer, Hannah
AU - Ziemann, Ulf
AU - Kern, Peter
AU - Wandinger, Klaus P.
AU - Bergh, Florian Then
AU - Boettcher, Tobias
AU - Langel, Stefan
AU - Liebetrau, Martin
AU - Rommer, Paulus S.
AU - Niehaus, Sabine
AU - Muench, Christoph
AU - Winkelmann, Alexander
AU - Zettl U, Uwe K.
AU - Metz, Imke
AU - Veauthier, Christian
AU - Sieb, Joern P.
AU - Wilke, Christian
AU - Hartung, Hans-Peter
AU - Aktas, Orhan
AU - Paul, Friedemann
PY - 2012/1/19
Y1 - 2012/1/19
N2 - The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity.To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus.Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%).Seropositive patients were found to be predominantly female (p <0.0003), to more often have signs of co-existing autoimmunity (p <0.00001), and to experience more severe clinical attacks. A visual acuity of ? 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p <0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades ? 2 more frequent, in particular if patients met the 2006 revised criteria (p <0.005, p <0.006 and p <0.01, respectively), the total spinal cord lesion load was higher (p <0.006), and lesions ? 6 vertebral segments as well as entire spinal cord involvement more frequent (p <0.003 and p <0.043). By contrast, bilateral ON at onset was more common in seronegatives (p <0.007), as was simultaneous ON and myelitis (p <0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p <0.029). The course of disease was more often monophasic in seronegatives (p <0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p <0.002 and p <0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome.This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.
AB - The diagnostic and pathophysiological relevance of antibodies to aquaporin-4 (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD) has been intensively studied. However, little is known so far about the clinical impact of AQP4-Ab seropositivity.To analyse systematically the clinical and paraclinical features associated with NMO spectrum disorders in Caucasians in a stratified fashion according to the patients' AQP4-Ab serostatus.Retrospective study of 175 Caucasian patients (AQP4-Ab positive in 78.3%).Seropositive patients were found to be predominantly female (p <0.0003), to more often have signs of co-existing autoimmunity (p <0.00001), and to experience more severe clinical attacks. A visual acuity of ? 0.1 during acute optic neuritis (ON) attacks was more frequent among seropositives (p <0.002). Similarly, motor symptoms were more common in seropositive patients, the median Medical Research Council scale (MRC) grade worse, and MRC grades ? 2 more frequent, in particular if patients met the 2006 revised criteria (p <0.005, p <0.006 and p <0.01, respectively), the total spinal cord lesion load was higher (p <0.006), and lesions ? 6 vertebral segments as well as entire spinal cord involvement more frequent (p <0.003 and p <0.043). By contrast, bilateral ON at onset was more common in seronegatives (p <0.007), as was simultaneous ON and myelitis (p <0.001); accordingly, the time to diagnosis of NMO was shorter in the seronegative group (p <0.029). The course of disease was more often monophasic in seronegatives (p <0.008). Seropositives and seronegatives did not differ significantly with regard to age at onset, time to relapse, annualized relapse rates, outcome from relapse (complete, partial, no recovery), annualized EDSS increase, mortality rate, supratentorial brain lesions, brainstem lesions, history of carcinoma, frequency of preceding infections, oligoclonal bands, or CSF pleocytosis. Both the time to relapse and the time to diagnosis was longer if the disease started with ON (p <0.002 and p <0.013). Motor symptoms or tetraparesis at first myelitis and > 1 myelitis attacks in the first year were identified as possible predictors of a worse outcome.This study provides an overview of the clinical and paraclinical features of NMOSD in Caucasians and demonstrates a number of distinct disease characteristics in seropositive and seronegative patients.
U2 - 10.1186/1742-2094-9-14
DO - 10.1186/1742-2094-9-14
M3 - Article
C2 - 22260418
SN - 1742-2094
VL - 9
SP - 14
JO - Journal of Neuroinflammation
JF - Journal of Neuroinflammation
ER -